文献
J-GLOBAL ID:201802255326161524
整理番号:18A0800799
再発または難治性慢性リンパ性白血病およびリンパ腫における新規PI3Kδおよびカゼインキナーゼ-1ε阻害剤,UMBRALISIB オープンラベル,第1相,用量漸増,第1回ヒト試験【JST・京大機械翻訳】
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
著者 (18件):
Burris Howard A
(Sarah Cannon Research Institute, Nashville, TN, USA)
,
Burris Howard A
(Tennessee Oncology, PLLC, Nashville, TN, USA)
,
Flinn Ian W
(Sarah Cannon Research Institute, Nashville, TN, USA)
,
Flinn Ian W
(Tennessee Oncology, PLLC, Nashville, TN, USA)
,
Patel Manish R
(Sarah Cannon Research Institute, Nashville, TN, USA)
,
Patel Manish R
(Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA)
,
Fenske Timothy S
(Medical College of Wisconsin, Milwaukee, WI, USA)
,
Deng Changchun
(Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons/New York-Presbyterian Hospital, New York, NY, USA)
,
Brander Danielle M
(Duke University Medical Center, Durham, NC, USA)
,
Gutierrez Martin
(John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA)
,
Essell James H
(Oncology Hematology Care, Cincinnati, OH, USA)
,
Kuhn John G
(The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA)
,
Miskin Hari P
(TG Therapeutics, New York, NY, USA)
,
Sportelli Peter
(TG Therapeutics, New York, NY, USA)
,
Weiss Michael S
(TG Therapeutics, New York, NY, USA)
,
Vakkalanka Swaroop
(Rhizen Pharmaceuticals SA, La Chaux-de-Fonds, Switzerland)
,
Savona Michael R
(Vanderbilt University Medical Center, Nashville, TN, USA)
,
O’Connor Owen A
(Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons/New York-Presbyterian Hospital, New York, NY, USA)
資料名:
Lancet Oncology
(Lancet Oncology)
巻:
19
号:
4
ページ:
486-496
発行年:
2018年
JST資料番号:
W1266A
ISSN:
1470-2045
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)